🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Intelligenza Artificiale in Cardiologia

You may have noted that the design of our journal has been updated, along with the publishing schedule, and now, the website is undergoing a radical change too. As of today, EuroIntervention has a new look online: it's brighter, more aesthetic, and easier to navigate. Why so many

🫀 Does Alirocumab affect #platelet function in patients with #MI? ⤵️ 📌 Among pts. receiving DAPT in the PACMAN-AMI Trial, #Alirocumab had no significant effect on platelet reactivity In TH current issue 👉 thieme-connect.de/products/ejour… #PCSK9 #CardioTwitter Lorenz Räber, MD PhD

🙌Recommended Paper 📰Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (mdpi.com/2077-0383/13/1…) ✍️Felice Gragnano 🎯Views 3409 JCM MDPI MDPI Medicine & Pharmacology

#CardioOncology review on management of cancer patients with AFib— a therapeutic conundrum: rdcu.be/dR3o1 Giovanni Esposito Giuseppe Gargiulo Christian Basile Mario Enrico Canonico Ciro Santoro International Cardio-Oncology Society

In this review (Part I), we appraise and discuss the clinical relevance of bleeding, definition of high bleeding risk and evidence supporting the implementation of dedicated antithrombotic regimens in high bleeding risk patients, providing practical recommendations across the

Percutaneous cardiac interventions require post-procedural #antithrombotic therapy 🏥 In this review published in JACC Journals, we discuss the evidence supporting dedicated antithrombotic regimens in #HBR patients 🩸with practical recommendations 👉 sciencedirect.com/science/articl…

Antithrombotic therapy is mandatory in patients undergoing percutaneous interventions, but its use is challenging in those with high bleeding risk. We appraise available evidence and propose clinical flow-charts in cardiac (Part I) and non-cardiac (Part II) interventions.

Antithrombotic therapy in #HBR 💊 #Cardiology #CardioEd #Cardio #CardioTwitter JACC Journals

🔴Antithrombotic Therapy in High Bleeding Risk ⤵️State-Of-The-Art #2024Review JACC Journals 🔹Part I: Percutaneous Cardiac Interventions 🔹Part II: Noncardiac Percutaneous Interventions 🔹jacc.org/doi/10.1016/j.… 🔹sciencedirect.com/science/articl… #Cardiology

Read 🔟 key points to remember from a state-of-the-art review on antithrombotic therapy in high bleeding risk for noncardiac percutaneous interventions. 🔗 bit.ly/4hDvIPO #cvCoag #JACCINT JACC Journals

💊 Are we ready to use immediate #prasugrel monotherapy after #PCI in patients with #diabetes? New data from the STOPDAPT-3 trial in #EHJPharmacotherapy 🔗 bit.ly/4gbvrBN EHJ-CVP Editor-in-Chief Felice Gragnano Giuseppe Gargiulo Jeehoon Kang

🚀 Prasugrel intermediate metabolite (PIM) negatively interferes with #prasugrel active metabolite (PAM), reducing its inhibitory activity, likely competing at the P2Y12 receptor–binding site 🧪🔬 🔥 New evidence in ATVB: An AHA Journal 🔎👉 ahajournals.org/doi/10.1161/AT… Marco Valgimigli

Prasugrel Intermediate Metabolite Modulates Platelet Inhibition by Negatively Interfering With an Active Metabolite: Data from FABOLUS-FASTER trial 🔬👨‍🔬 👉 ahajournals.org/doi/full/10.11… ATVB: An AHA Journal Marco Valgimigli #Cardiology #CardioTwitter #CardioEd

Proud to contribute to this fantastic issue with the main results of the POMPEII prospective study on cangrelor in patients with ACS or CCS Giovanni Esposito Marco Valgimigli Plinio Cirillo Raffaele Piccolo Anna Franzone Luigi Di Serafino Domenico Simone Castiello Lilli Manzi Mario Enrico Canonico Marisa Avvedimento

I could not have imagined a better way to mark this 20th anniversary than by sharing it with the many individuals who read and contribute to EuroIntervention. This milestone is not only ours—as editors, editorial team, and publishers—but belongs to the entire interventional

The POMPEII Registry offers detailed pharmacodynamic data on cangrelor in patients with acute and chronic coronary syndromes undergoing PCI. Cangrelor provided moderate platelet inhibition, with low rates of high residual platelet reactivity (HRPR) during infusion. However, HRPR

I am pleased to announce that the new Impact Factor of EuroIntervention is the highest in its 20-year history: 9.5. Ranked 16th out of 230 journals in the cardiovascular category (+5 positions versus the previous year). Thank you all — it’s an exciting rollercoaster.